{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-188277","form_type":"8-K","ticker":"RGEN","cik":"0000730272","company_name":"REPLIGEN CORP","filed_at":"2024-07-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.737903+00:00","generated_at":"2026-05-31T15:31:00.686583+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Repligen Q2 revenue $154M, adj. EPS $0.33, orders $157M; CEO transition, Tantti acquisition","bullets":["Q2 2024 revenue $154M vs $159M prior year; GAAP EPS $0.06, adjusted EPS $0.33 vs $0.53.","Book-to-bill 1.02 for quarter; orders $157M; new modalities sales up 5% YoY.","CEO Tony Hunt becomes Executive Chair; Olivier Loeillot appointed President & CEO effective Sept 1.","Post-quarter-end, entered agreement to acquire chromatography innovator Tantti Laboratory Inc. (value undisclosed).","FY 2024 revenue guidance narrowed to $620-635M; adjusted EPS guidance unchanged at $1.42-1.49."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-188277","json":"https://secwatch.observer/filing/0001193125-24-188277.json","markdown":"https://secwatch.observer/filing/0001193125-24-188277.md","text":"https://secwatch.observer/filing/0001193125-24-188277.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/730272/000119312524188277/0001193125-24-188277-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/730272/000119312524188277/d848995d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T15:31:00.686583+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}